



29th March 2017

The Secretary
Bombay Stock Exchange Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai 400 001

Clarification on news item appearing in www.reuters.com

Dear Sir/Madam

This is with reference to your letter no. L/SURV/ONL/RV/ZS/2016-17/301 dated 29th March 2017.

We would like to clarify that the new article titled "FDA approves Regeneron, Sanofi \$37,000 per year eczema drug" as mentioned in your letter is not relating to the operations of Sanofi India Limited. You would note that the news article appeared in US edition of Reuters and it is not relating to Sanofi business in India."

Thanking you,

Yours sincerely,
SANOFI INDIA LIMITED

A handwritten signature in black ink, appearing to read "GIRISH TEKCHANDANI", is written over a horizontal line.

GIRISH TEKCHANDANI
COMPANY SECRETARY